Pharmaceuticals | USA
Zogenix Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
The financials pass all the three standards we check against.
Total Analysts: 9
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
|Dividends per Share|
Zogenix, Inc. is a global biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla (fenfluramine) is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. Fintepla is also under development in Japan. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal. MT1621 is in late-stage development.
|✔ FTSE||✔ AAOIFI||✔ DJIM|
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.